

DENV2/DENV3 or 4

GTS2/3DP

TRBV	CDR3	TRBJ	Freq (%)
10-2	CASSGGQGNIQY	2-4	33.75
7-3	CASSLIGGNTEAF	1-1	10.00
11-2	CASSRGLNIEQY	2-7	8.75
11-2	CASSRAGGTASYEQY	2-7	7.50
10-2	CASSGGSGNIQY	2-4	6.25
7-9	CASSLGGGLQETQY	2-5	5.00
7-9	CASSAFSGFQETQY	2-5	5.00
4-1	CASSQDPGLNTEAF	1-1	3.75
6-5	CASSYRGRAGETQY	2-5	2.50
11-2	CASSRGGGAYEQF	2-1	2.50
9	CASSVTGEPYEQY	2-7	2.50
10-2	CASSGGQANIQY	2-4	2.50
7-3	CASSLGGTDTQY	2-3	2.50
18	CASSPGGGTQETQY	2-5	1.25
10-2	CASSGGRGNIQY	2-4	1.25
10-2	CASSGGQENIQY	2-4	1.25
10-2	CASSGGLGNIQY	2-4	1.25
10-2	CASSGGHGNIQY	2-4	1.25
9	CASGPGGGYEQF	2-1	1.25

TRBV	CDR3	TRBJ	Freq (%)
7-8	CASSLGGGNQETQY	2-5	98.78
7-8	CASNLGGGNQETQY	2-5	1.22

Supplementary Figure 5 TRBV and TRBJ usage, CDR3 β amino acid sequence, and clonotype frequency are shown for CD3⁺CD8⁺CD14⁻CD19⁻ HLA-A*11:01-GTS2 and HLA-A*11:01-GTS3/4 tetramer⁺ populations isolated from patients sequentially infected with various combinations of DENV2/3/4. Recurrent clonotypes are highlighted in color. DP, double positive; GTS3, GTS3/4 (blue type).